article thumbnail

Doctor Sues DEA for Right to Give Psilocybin to Ailing Patients

Project CBD

Psilocybin, the psychedelic mushroom extract, has been fast-tracked by the FDA to treat depression, but doctors still can’t use it in their practice.

DEA 344
article thumbnail

DEA Promises Progress on Federal Cultivation Applications, But Provides No Timetable for Action

NORML

The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.

DEA 187
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NORML Says DEA’s Newly Proposed Bulk Cultivation Rules Are “Unduly Onerous, Expensive, and Impractical”

NORML

The DEA now estimates that, under the new rules, it may approve between three and 15 total applicants. ” He added, “Further, the DEA has an incredibly poor track record in this arena – having for years now promised to expedite and streamline this process, but failing to deliver.

article thumbnail

10 Tips for Buying Hemp-Derived CBD Products

Project CBD

With Congress seemingly poised to legalize the cultivation of industrial hemp for many uses, including the production of biomass for CBD oil extraction, many questions remain unanswered. How will the DEA reschedule CBD now that Epidiolex has been approved as a pharmaceutical CBD isolate?

Hemp 203
article thumbnail

FDA Approves CBD-Containing Drug - Will the DEA Finally Step Up?

MJ Business Attorneys

Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. The FDA can make recommendations to the DEA about substances subjected to scheduling under the CSA, but the DEA is the entity with the power to reschedule CBD. In the recent case Hemp Industries Associations v.

DEA 113
article thumbnail

Doctor Sues DEA for Right to Give Psilocybin to Dying Patients

Project CBD

Psilocybin, the psychedelic mushroom extract, has been fast-tracked by the FDA to treat depression, but doctors still can’t use it in their practice.

DEA 150
article thumbnail

DEA Approves Cocaine Derivative for Parkinson’s Research. Why Not Cannabis?

Veriheal

But recent news of the DEA’s approval of a cocaine derivative for Parkinson’s disease research has left us scratching our heads. After receiving a petition three years prior, the DEA finally answered with action, making plans to deschedule [18F]FP-CIT , a controlled substance derived from cocaine. .”

DEA 98